Difference between revisions of "Soft tissue sarcoma - null regimens"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "3 PubMed]" to "3/ PubMed]")
m
 
(20 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the [[Soft tissue sarcoma|main STS page]] for current regimens.
+
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Soft tissue sarcoma|main STS page]] for regimens that include active anticancer treatment.
  
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
  
 
=Neoadjuvant therapy=
 
=Neoadjuvant therapy=
−
=No neoadjuvant therapy=
+
==No neoadjuvant therapy==
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
Line 18: Line 18:
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://www.clinicaltrials.gov/ct2/show/NCT04031677 Awaiting publication (STRASS2)]
+
|[https://www.clinicaltrials.gov/study/NCT04031677 Awaiting publication (STRASS2)]
 
|2020-2027
 
|2020-2027
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
−
|1a. [[#Doxorubicin_.26_Ifosfamide_.28AI.29_88|AI]]<br>1b. [[#Epirubicin_.26_Ifosfamide_.28EI.29_88|EI]]
+
|1a. [[#Doxorubicin_.26_Ifosfamide_.28AI.29_888|AI]]<br>1b. [[#Epirubicin_.26_Ifosfamide_888|EI]]
−
| style="background-color:#d3d3d3" |In progress
+
| style="background-color:#d3d3d3" |TBD if different primary endpoint of DFS
 
|-
 
|-
 
|}
 
|}
Line 30: Line 30:
 
*[[Surgery#Surgical_resection|Surgery]]
 
*[[Surgery#Surgical_resection|Surgery]]
 
</div></div>
 
</div></div>
 +
 
===References===
 
===References===
−
#'''STRASS2:''' NCT04031677
+
#'''STRASS2:''' [https://clinicaltrials.gov/study/NCT04031677 NCT04031677]
  
 
=Adjuvant therapy=
 
=Adjuvant therapy=
Line 53: Line 54:
 
|1995-2003
 
|1995-2003
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
−
|[[#Doxorubicin_.26_Ifosfamide_.28AI.29_88|AI]]
+
|[[#Doxorubicin_.26_Ifosfamide_.28AI.29_888|AI]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
|-
 
|-
Line 59: Line 60:
 
|2002-2007
 
|2002-2007
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
−
|[[#Epirubicin_.26_Ifosfamide_.28EI.29_88|EI]]
+
|[[#Epirubicin_.26_Ifosfamide_888|EI]]
 
| style="background-color:#eeee01" |Non-inferior OS
 
| style="background-color:#eeee01" |Non-inferior OS
 
|-
 
|-
Line 66: Line 67:
 
<div class="toccolours" style="background-color:#cbd5e8">
 
<div class="toccolours" style="background-color:#cbd5e8">
 
====Preceding treatment====
 
====Preceding treatment====
−
*Gronchi et al. 2012: [[#Epirubicin_.26_Ifosfamide|Neoadjuvant EI]] x 3, then [[Surgery#Surgical_resection|surgery]]
+
*Gronchi et al. 2012: Neoadjuvant [[#Epirubicin_.26_Ifosfamide|EI]] x 3, then [[Surgery#Surgical_resection|surgery]]
 
*EORTC 62931: [[Surgery#Surgical_resection|Surgery]] +/- RT
 
*EORTC 62931: [[Surgery#Surgical_resection|Surgery]] +/- RT
 
</div></div>
 
</div></div>
 
===References===
 
===References===
−
# '''EORTC 62771:''' Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M, Van Unnik J, Contesso G, Thomas D, Van Glabbeke M, Markham D, Pinedo H. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994 Jun;12(6):1137-49. [https://doi.org/10.1200/JCO.1994.12.6.1137 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8201375 PubMed]
+
# '''EORTC 62771:''' Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M, Van Unnik J, Contesso G, Thomas D, Van Glabbeke M, Markham D, Pinedo H. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994 Jun;12(6):1137-49. [https://doi.org/10.1200/JCO.1994.12.6.1137 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8201375/ PubMed]
−
## '''Pooled update:''' Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425-32. Epub 2014 Oct 6. [https://doi.org/10.1093/annonc/mdu460 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25294887 PubMed]
+
## '''Pooled update:''' Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425-32. Epub 2014 Oct 6. [https://doi.org/10.1093/annonc/mdu460 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25294887/ PubMed]
−
# Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P; Italian Sarcoma Group; Spanish Sarcoma Group. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012 Mar 10;30(8):850-6. Epub 2012 Feb 6. [https://doi.org/10.1200/JCO.2011.37.7218 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22312103/ PubMed] EudraCT 2004-003979-36
+
# Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P; Italian Sarcoma Group; Spanish Sarcoma Group. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012 Mar 10;30(8):850-6. Epub 2012 Feb 6. [https://doi.org/10.1200/JCO.2011.37.7218 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22312103/ PubMed] EudraCT 2004-003979-36
−
# '''EORTC 62931:''' Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012 Oct;13(10):1045-54. Epub 2012 Sep 4. [https://doi.org/10.1016/S1470-2045(12)70346-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22954508 PubMed] NCT00002641
+
# '''EORTC 62931:''' Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012 Oct;13(10):1045-54. Epub 2012 Sep 4. [https://doi.org/10.1016/S1470-2045(12)70346-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22954508/ PubMed] [https://clinicaltrials.gov/study/NCT00002641 NCT00002641]
−
## '''Pooled update:''' Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425-32. Epub 2014 Oct 6. [https://doi.org/10.1093/annonc/mdu460 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25294887 PubMed]
+
## '''Pooled update:''' Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425-32. Epub 2014 Oct 6. [https://doi.org/10.1093/annonc/mdu460 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25294887/ PubMed]
  
 
=Locally advanced or metastatic disease=
 
=Locally advanced or metastatic disease=
Line 88: Line 89:
 
|-
 
|-
 
|[https://doi.org/10.1016/j.annonc.2021.04.014 Le Cesne et al. 2021 (T-SAR)]
 
|[https://doi.org/10.1016/j.annonc.2021.04.014 Le Cesne et al. 2021 (T-SAR)]
−
|2015
+
|2015-01-26 to 2015-11-05
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
 
|[[Soft_tissue_sarcoma#Trabectedin_monotherapy|Trabectedin]]
 
|[[Soft_tissue_sarcoma#Trabectedin_monotherapy|Trabectedin]]
Line 97: Line 98:
 
</div>
 
</div>
 
===References===
 
===References===
−
# '''T-SAR:''' Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol. 2021 Aug;32(8):1034-1044. Epub 2021 Apr 29. [https://doi.org/10.1016/j.annonc.2021.04.014 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/33932507/ PubMed] NCT02672527
+
# '''T-SAR:''' Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol. 2021 Aug;32(8):1034-1044. Epub 2021 Apr 29. [https://doi.org/10.1016/j.annonc.2021.04.014 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33932507/ PubMed] [https://clinicaltrials.gov/study/NCT02672527 NCT02672527]
  
 
==Placebo==
 
==Placebo==
Line 112: Line 113:
 
|2007-2010
 
|2007-2010
 
| style="background-color:#1a9851" |Phase 3 (C)
 
| style="background-color:#1a9851" |Phase 3 (C)
−
|[[#Ridaforolimus_monotherapy_77|Ridaforolimus]]
+
|[[#Ridaforolimus_monotherapy_777|Ridaforolimus]]
 
| style="background-color:#d73027" |Inferior PFS
 
| style="background-color:#d73027" |Inferior PFS
 
|-
 
|-
Line 128: Line 129:
 
|-
 
|-
 
|[https://doi.org/10.1016/S1470-2045(16)30507-1 Mir et al. 2016 (REGOSARC)]
 
|[https://doi.org/10.1016/S1470-2045(16)30507-1 Mir et al. 2016 (REGOSARC)]
−
|2013-2014
+
|2013-08-05 to 2014-11-26
 
| style="background-color:#1a9851" |Randomized Phase 2 (C)
 
| style="background-color:#1a9851" |Randomized Phase 2 (C)
 
|[[Soft_tissue_sarcoma#Regorafenib_monotherapy|Regorafenib]]
 
|[[Soft_tissue_sarcoma#Regorafenib_monotherapy|Regorafenib]]
Line 137: Line 138:
 
''No active antineoplastic treatment.''
 
''No active antineoplastic treatment.''
 
</div>
 
</div>
 +
 
===References===
 
===References===
−
# '''PALETTE:''' van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. Epub 2012 May 16. [https://doi.org/10.1016/S0140-6736(12)60651-5 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22595799 PubMed] NCT00753688
+
# '''PALETTE:''' van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; [[Study_Groups#EORTC|EORTC]] Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. Epub 2012 May 16. [https://doi.org/10.1016/S0140-6736(12)60651-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22595799/ PubMed] [https://clinicaltrials.gov/study/NCT00753688 NCT00753688]
−
## '''Subgroup analysis:''' Kawai A, Araki N, Hiraga H, Sugiura H, Matsumine A, Ozaki T, Ueda T, Ishii T, Esaki T, Machida M, Fukasawa N. A randomized, double-blind, placebo-controlled, phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol. 2016 Mar;46(3):248-53. Epub 2016 Feb 10. [https://academic.oup.com/jjco/article/46/3/248/2384950 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777611/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26864131/ PubMed]
+
## '''Subgroup analysis:''' Kawai A, Araki N, Hiraga H, Sugiura H, Matsumine A, Ozaki T, Ueda T, Ishii T, Esaki T, Machida M, Fukasawa N. A randomized, double-blind, placebo-controlled, phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol. 2016 Mar;46(3):248-53. Epub 2016 Feb 10. [https://doi.org/10.1093/jjco/hyv184 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777611/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26864131/ PubMed]
−
# '''SUCCEED:''' Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 1;31(19):2485-92. Epub 2013 May 28. [https://doi.org/10.1200/JCO.2012.45.5766 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23715582/ PubMed] NCT00538239
+
# '''SUCCEED:''' Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 1;31(19):2485-92. Epub 2013 May 28. [https://doi.org/10.1200/JCO.2012.45.5766 link to original article] [https://pubmed.ncbi.nlm.nih.gov/23715582/ PubMed] [https://clinicaltrials.gov/study/NCT00538239 NCT00538239]
−
# Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Tanase T, Hasegawa T, Takahashi S. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015 Apr;16(4):406-16. Epub 2015 Mar 18. [https://doi.org/10.1016/S1470-2045(15)70098-7 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25795406 PubMed] JapicCTI-121850
+
# Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Tanase T, Hasegawa T, Takahashi S. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015 Apr;16(4):406-16. Epub 2015 Mar 18. [https://doi.org/10.1016/S1470-2045(15)70098-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25795406/ PubMed] JapicCTI-121850
−
# '''REGOSARC:''' Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1732-1742. Epub 2016 Oct 14.  [https://doi.org/10.1016/S1470-2045(16)30507-1 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27751846 PubMed] NCT01900743
+
# '''REGOSARC:''' Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1732-1742. Epub 2016 Oct 14.  [https://doi.org/10.1016/S1470-2045(16)30507-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27751846/ PubMed] [https://clinicaltrials.gov/study/NCT01900743 NCT01900743]
  
 
[[Category:Soft tissue sarcoma regimens]]
 
[[Category:Soft tissue sarcoma regimens]]

Latest revision as of 23:45, 30 June 2024

Back to Top

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main STS page for regimens that include active anticancer treatment.


Neoadjuvant therapy

No neoadjuvant therapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Awaiting publication (STRASS2) 2020-2027 Phase 3 (C) 1a. AI
1b. EI 		TBD if different primary endpoint of DFS

No systemic anticancer treatment before surgery.

Subsequent treatment

References

  1. STRASS2: NCT04031677

Adjuvant therapy

Observation

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Bramwell et al. 1994 (EORTC 62771) 1977-1988 Phase 3 (C) CYVADIC Inferior RFS
Woll et al. 2012 (EORTC 62931) 1995-2003 Phase 3 (C) AI Did not meet primary endpoint of OS
Gronchi et al. 2012 2002-2007 Phase 3 (C) EI Non-inferior OS

No further treatment.

Preceding treatment

  • Gronchi et al. 2012: Neoadjuvant EI x 3, then surgery
  • EORTC 62931: Surgery +/- RT

References

  1. EORTC 62771: Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M, Van Unnik J, Contesso G, Thomas D, Van Glabbeke M, Markham D, Pinedo H. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994 Jun;12(6):1137-49. link to original article PubMed
    1. Pooled update: Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425-32. Epub 2014 Oct 6. link to original article PubMed
  2. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P; Italian Sarcoma Group; Spanish Sarcoma Group. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012 Mar 10;30(8):850-6. Epub 2012 Feb 6. link to original article PubMed EudraCT 2004-003979-36
  3. EORTC 62931: Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012 Oct;13(10):1045-54. Epub 2012 Sep 4. link to original article PubMed NCT00002641
    1. Pooled update: Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, Gronchi A, Hogendoorn PC, Litiere S, Marreaud S, Blay JY, Van Der Graaf WT. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014 Dec;25(12):2425-32. Epub 2014 Oct 6. link to original article PubMed

Locally advanced or metastatic disease

Best supportive care

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Le Cesne et al. 2021 (T-SAR) 2015-01-26 to 2015-11-05 Phase 3 (C) Trabectedin Inferior PFS

No antineoplastic treatment.

References

  1. T-SAR: Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol. 2021 Aug;32(8):1034-1044. Epub 2021 Apr 29. link to original article PubMed NCT02672527

Placebo

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Demetri et al. 2013 (SUCCEED) 2007-2010 Phase 3 (C) Ridaforolimus Inferior PFS
van der Graaf et al. 2012 (PALETTE) 2008-2010 Phase 3 (C) Pazopanib Inferior PFS
Kawai et al. 2015 2012-2014 Randomized Phase 2 (C) Trabectedin Inferior PFS
Mir et al. 2016 (REGOSARC) 2013-08-05 to 2014-11-26 Randomized Phase 2 (C) Regorafenib Inferior PFS1

1Reported efficacy in REGOSARC is for the leiomyosarcoma, synovial sarcoma, and other sarcoma cohorts; there was no significant difference in outcome for the liposarcoma cohort.
No active antineoplastic treatment.

References

  1. PALETTE: van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. Epub 2012 May 16. link to original article PubMed NCT00753688
    1. Subgroup analysis: Kawai A, Araki N, Hiraga H, Sugiura H, Matsumine A, Ozaki T, Ueda T, Ishii T, Esaki T, Machida M, Fukasawa N. A randomized, double-blind, placebo-controlled, phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol. 2016 Mar;46(3):248-53. Epub 2016 Feb 10. link to original article link to PMC article PubMed
  2. SUCCEED: Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 1;31(19):2485-92. Epub 2013 May 28. link to original article PubMed NCT00538239
  3. Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Tanase T, Hasegawa T, Takahashi S. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015 Apr;16(4):406-16. Epub 2015 Mar 18. link to original article PubMed JapicCTI-121850
  4. REGOSARC: Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1732-1742. Epub 2016 Oct 14. link to original article PubMed NCT01900743
Retrieved from "https://hemonc.org/w/index.php?title=Soft_tissue_sarcoma_-_null_regimens&oldid=87885"